Cargando…
SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines
SARS-CoV2 is a member of human coronaviruses and is the causative agent of the present pandemic COVID-19 virus. In order to control COVID-19, studies on viral structure and mechanism of infectivity and pathogenicity are sorely needed. The spike (S) protein is comprised of S1 & S2 subunits. These...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V. on behalf of King Saud University.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523302/ https://www.ncbi.nlm.nih.gov/pubmed/34690467 http://dx.doi.org/10.1016/j.jksus.2021.101648 |
_version_ | 1784585272858509312 |
---|---|
author | Velusamy, Palaniyandi Kiruba, Kannan Su, Chia-Hung Arun, Viswanathan Anbu, Periasamy Gopinath, Subash C.B. Vaseeharan, Baskaralingam |
author_facet | Velusamy, Palaniyandi Kiruba, Kannan Su, Chia-Hung Arun, Viswanathan Anbu, Periasamy Gopinath, Subash C.B. Vaseeharan, Baskaralingam |
author_sort | Velusamy, Palaniyandi |
collection | PubMed |
description | SARS-CoV2 is a member of human coronaviruses and is the causative agent of the present pandemic COVID-19 virus. In order to control COVID-19, studies on viral structure and mechanism of infectivity and pathogenicity are sorely needed. The spike (S) protein is comprised of S1 & S2 subunits. These spike protein subunits enable viral attachment by binding to the host cell via ACE-2 (angiotensin converting enzyme-2) receptor, thus facilitating the infection. During viral entry, one of the key steps is the cleavage of the S1-S2 spike protein subunits via surface TMPRSS2 (transmembrane protease serine 2) and results in viral infection. Hence, the S-protein is critical for the viral attachment and penetration into the host. The rapid advancement of our knowledge on the structural and functional aspects of the spike protein could lead to development of numerous candidate vaccines against SARS-CoV2. Here the authors discuss about the structure of spike protein and explore its related functions. Our aim is to provide a better understanding that may aid in fighting against CoVID-19 and its treatment. |
format | Online Article Text |
id | pubmed-8523302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Authors. Published by Elsevier B.V. on behalf of King Saud University. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85233022021-10-20 SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines Velusamy, Palaniyandi Kiruba, Kannan Su, Chia-Hung Arun, Viswanathan Anbu, Periasamy Gopinath, Subash C.B. Vaseeharan, Baskaralingam J King Saud Univ Sci Review SARS-CoV2 is a member of human coronaviruses and is the causative agent of the present pandemic COVID-19 virus. In order to control COVID-19, studies on viral structure and mechanism of infectivity and pathogenicity are sorely needed. The spike (S) protein is comprised of S1 & S2 subunits. These spike protein subunits enable viral attachment by binding to the host cell via ACE-2 (angiotensin converting enzyme-2) receptor, thus facilitating the infection. During viral entry, one of the key steps is the cleavage of the S1-S2 spike protein subunits via surface TMPRSS2 (transmembrane protease serine 2) and results in viral infection. Hence, the S-protein is critical for the viral attachment and penetration into the host. The rapid advancement of our knowledge on the structural and functional aspects of the spike protein could lead to development of numerous candidate vaccines against SARS-CoV2. Here the authors discuss about the structure of spike protein and explore its related functions. Our aim is to provide a better understanding that may aid in fighting against CoVID-19 and its treatment. The Authors. Published by Elsevier B.V. on behalf of King Saud University. 2021-12 2021-10-19 /pmc/articles/PMC8523302/ /pubmed/34690467 http://dx.doi.org/10.1016/j.jksus.2021.101648 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Velusamy, Palaniyandi Kiruba, Kannan Su, Chia-Hung Arun, Viswanathan Anbu, Periasamy Gopinath, Subash C.B. Vaseeharan, Baskaralingam SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines |
title | SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines |
title_full | SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines |
title_fullStr | SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines |
title_full_unstemmed | SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines |
title_short | SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines |
title_sort | sars-cov-2 spike protein: site-specific breakpoints for the development of covid-19 vaccines |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523302/ https://www.ncbi.nlm.nih.gov/pubmed/34690467 http://dx.doi.org/10.1016/j.jksus.2021.101648 |
work_keys_str_mv | AT velusamypalaniyandi sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines AT kirubakannan sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines AT suchiahung sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines AT arunviswanathan sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines AT anbuperiasamy sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines AT gopinathsubashcb sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines AT vaseeharanbaskaralingam sarscov2spikeproteinsitespecificbreakpointsforthedevelopmentofcovid19vaccines |